TY - JOUR
T1 - Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo
AU - Schutters, Sara I. J.
AU - van Megen, Harold J. G. M.
AU - Van Veen, J. Frederieke
AU - Schruers, Koen R. J.
AU - Westenberg, Herman G. M.
PY - 2011/1
Y1 - 2011/1
N2 - Objectives The aim of the study was to investigate if combination of mirtazapine with paroxetine causes a greater therapeutic effect and less sexual side effects than paroxetine monotherapy in social anxiety disorder (SAD). Methods Twenty one patients with generalised SAD, non-responsive to a 12 week trial with mirtazapine and 22 patients, non-responsive to placebo received paroxetine (20-40 mg) in addition to their double-blind treatment with mirtazapine or placebo for another 12 weeks. The Liebowitz Social Anxiety Scale (LSAS) and the Clinical Global Impression-Improvement (CGI-I) scale were used to measure efficacy. Sexual functioning was assessed by the Arizona Sexual Experiences Scale (ASEX). Results Both treatments showed a significant LSAS reduction and their response rates (based on LSAS reduction >= 40% and CGI-I = 19) was found in half of patients treated with paroxetine and placebo, and in 38% of patients treated with paroxetine and mirtazapine. Conclusion The present study did not find support for a greater efficacy of combination pharmacotherapy in SAD, however results suggest that combination of paroxetine with mirtazapine might cause less sexual dysfunction than treatment with paroxetine alone.
AB - Objectives The aim of the study was to investigate if combination of mirtazapine with paroxetine causes a greater therapeutic effect and less sexual side effects than paroxetine monotherapy in social anxiety disorder (SAD). Methods Twenty one patients with generalised SAD, non-responsive to a 12 week trial with mirtazapine and 22 patients, non-responsive to placebo received paroxetine (20-40 mg) in addition to their double-blind treatment with mirtazapine or placebo for another 12 weeks. The Liebowitz Social Anxiety Scale (LSAS) and the Clinical Global Impression-Improvement (CGI-I) scale were used to measure efficacy. Sexual functioning was assessed by the Arizona Sexual Experiences Scale (ASEX). Results Both treatments showed a significant LSAS reduction and their response rates (based on LSAS reduction >= 40% and CGI-I = 19) was found in half of patients treated with paroxetine and placebo, and in 38% of patients treated with paroxetine and mirtazapine. Conclusion The present study did not find support for a greater efficacy of combination pharmacotherapy in SAD, however results suggest that combination of paroxetine with mirtazapine might cause less sexual dysfunction than treatment with paroxetine alone.
KW - antidepressants
KW - social anxiety disorder
KW - mirtazapine
KW - paroxetine
U2 - 10.1002/hup.1165
DO - 10.1002/hup.1165
M3 - Article
C2 - 23055414
SN - 0885-6222
VL - 26
SP - 72
EP - 76
JO - Human Psychopharmacology-Clinical and Experimental
JF - Human Psychopharmacology-Clinical and Experimental
IS - 1
ER -